On Friday, Shares of Biogen Inc (NASDAQ:BIIB), subtract 0.13% and closed at $305.59 in the last trading session. The last trading range of the stock ranges between $302.21 and $308.00. The company’s Market capitalization is $66.87 Billion with the total Outstanding Shares of 219.12 Million. During the 52-week trading session the minimum price at which share price traded, registered at $223.02 and reached to max level of $333.65. New data from the clinical program for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), were presented by Biogen (BIIB) and Ionis Pharmaceuticals (IONS) in the late-breaking session at the 2016 World Muscle Society Congress in Granada, Spain. The presentations included safety results from the interim analysis of the Phase 3 ENDEAR study in infantile-onset SMA (most likely to develop Type 1), encouraging preliminary results from NURTURE, a Phase 2 open-label study in pre-symptomatic infants, and a recent analysis of the ongoing Phase 2 open-label study in patients with later-onset SMA (consistent with Types 2 or 3).
“We continue to be encouraged by the consistently positive results with nusinersen across our clinical program, counting our first data in infants treated before they show signs of the disease,” said Wildon Farwell, senior director SMA clinical development at Biogen. “NURTURE is the first study to evaluate an investigational therapy in pre-symptomatic infants genetically at risk for SMA. In this analysis, infants treated for up to one year achieved motor milestones in timelines more consistent with normal development than what is observed in the natural history of patients with Type 1 SMA.”
Biogen has accomplished the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of nusinersen. Submission of the Marketing Authorization Application to the European Medicines Agency is planned in the next week. Biogen will initiate regulatory filings in other countries in the coming months.
Shares of Cempra Inc (NASDAQ:CEMP), added 1.22% and closed at $22.45 in the last trading session. The last trading range of the stock ranges between $21.61 and $22.55. The company’s Market capitalization is $1.18 Billion with the total Outstanding Shares of51.99Billion. During the 52-week trading session the minimum price at which share price traded, registered at $14.03 and reached to max level of $34.24. Cempra, Inc. (CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, recently declared the presentation of three abstracts based upon analyzing treatment failures with existing antibiotics from more than 400,000 records of patients diagnosed with community-attained bacterial pneumonia (CABP) in a large U.S. insurance claims database.
The data analysis will be presented at the annual Academy of Managed Care Pharmacy Nexus meeting in National Harbor, MD from October 3-6, 2016.
These patient records were analyzed to assess rates of failure to the most commonly prescribed antibiotics to treat CABP. Treatment failure was defined as antibiotic prescription refill, new antibiotic claim, emergency room visit, or hospitalization occurring within 30 days of initial therapy.
This analysis showed that more than one out of five adult CABP patients failed initial antibiotic monotherapy, with the failure rate surpassing one out of four for an elderly population with certain comorbidities.